U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07377175) titled 'Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.' on Jan. 09.
Brief Summary: A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects
Study Start Date: Aug. 28, 2025
Study Type: INTERVENTIONAL
Condition:
Smallpox
Cowpox
Monkeypox
Poxvirus Infection
Intervention:
DRUG: BSY001 for Injection (37.5mg)
A single dose of 37.5mg BSY001 for injection.
DRUG: BSY001 for Injection (75 mg)
A single dose of 75 mg BSY001 for ...